Showing 1 - 10 of 18
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10010300533
Dieser Beitrag diskutiert den Einfluss vergangener gesundheitspolitischer Reformgesetze in Deutschland auf Wahl- und …
Persistent link: https://www.econbiz.de/10010300558
Persistent link: https://www.econbiz.de/10001406395
Persistent link: https://www.econbiz.de/10011541102
Persistent link: https://www.econbiz.de/10010509297
Persistent link: https://www.econbiz.de/10011306421
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 antidiabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010481411
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010338113
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010339071
Persistent link: https://www.econbiz.de/10001586927